Adjuvant TNF-α therapy to electrochemotherapy with intravenous cisplatin in murine sarcoma exerts synergistic antitumor effectiveness

Radiology and Oncology

Volumn 49, Issue 1, 2015, Pages 32-40

  Cemazar, Maja ^a,b   Todorovic, Vesna ^a   Scancar, Janez ^c   Lampreht, Ursa ^a   Stimac, Monika ^a   Kamensek, Urska ^a   Kranjc, Simona ^a   Coer, Andrej ^b   Sersa, Gregor ^a  

^a INSTITUTE OF ONCOLOGY   (Slovenia)

^b UNIVERSITY OF PRIMORSKA   (Slovenia)

^c JO EF STEFAN INSTITUTE   (Slovenia)

Author keywords

adjuvant immunotherapy; cisplatin; electrochemotherapy; TNF

Indexed keywords

CISPLATIN; TUMOR NECROSIS FACTOR ALPHA;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD VESSEL INJURY; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; ELECTROCHEMOTHERAPY; HISTOLOGY; IMMUNOMODULATION; IN VIVO STUDY; NONHUMAN; SARCOMA; SURVIVAL RATE; TUMOR GROWTH; TUMOR NECROSIS; TUMOR VOLUME;

EID: 84929144228     PISSN: 13182099     EISSN: 15813207     Source Type: Journal    
DOI: 10.1515/raon-2015-0005     Document Type: Article

References (41)

1. Marty M, Sersa G, Garbay J, Gehl J, Collins C, Snoj M, et al. Electrochemo therapy-An easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: Results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study. EJC Suppl 2006; 4: 3-13. 10.1016/j.ejcsup.2006.08.002
2. Mali B, Jarm T, Snoj M, Sersa G, Miklavcic D. Antitumor effectiveness of ele ctrochemotherapy: A systematic review and meta-analysis. EJSO 2013; 39: 4-16. http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER-APP&SrcAuth=LinksAMR&KeyUT=WOS:000315421700001&DestLinkType=FullRecord&DestApp=ALL-WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3 10.1016/j.ejso.2012.08.016
3. Testori A, Tosti G, Martinoli C, Spadola G, Cataldo F, Verrecchia F, et al. Electrochemotherapy for cutaneous and subcutaneous tumor lesions: A novel therapeutic approach. Dermatol Ther 2010; 23: 651-61. 21054709 10.1111/j.1529-8019.2010.01370.x http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER-APP&SrcAuth=LinksAMR&KeyUT=WOS:000283949000008&DestLinkType=FullRecord&DestApp=ALL-WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3
4. Soden DM, Larkin JO, Collins CG, Tangney M, Aarons S, Piggott J, et al. Succ essful application of targeted electrochemotherapy using novel flexible electrodes and low dose bleomycin to solid tumours. Cancer Lett 2006; 232: 300-10. 10.1016/j.canlet.2005.03.057
5. Mahmood F, Gehl J. Optimizing clinical performance and geometrical robustnes s of a new electrode device for intracranial tumor electroporation. Bioelectrochem 2011; 81: 10-6. 10.1016/j.bioelechem.2010.12.002
6. Agerholm-Larsen B, Iversen HK, Ibsen P, Moller JM, Mahmood F, Jensen KS, et al. Preclinical validation of electrochemotherapy as an effective treatment for brain tumors. Cancer Res 2011; 71: 3753-62. 10.1158/0008-5472.CAN-11-0451 http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER-APP&SrcAuth=LinksAMR&KeyUT=WOS:000291153500004&DestLinkType=FullRecord&DestApp=ALL-WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3
7. Edhemovic I, Gadzijev EM, Brecelj E, Miklavcic D, Kos B, Zupanic A, et al. E lectrochemotherapy: a new technological approach in treatment of metastases in the liver. Technol Cancer Res T 2011; 10: 475-85.
8. Linnert M, Iversen HK, Gehl J. Multiple brain metastases-current managemen t and perspectives for treatment with electrochemotherapy. Radiol Oncol 2012; 46: 271-8. http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER-APP&SrcAuth=LinksAMR&KeyUT=WOS:000311648100001&DestLinkType=FullRecord&DestApp=ALL-WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3
9. Fini M, Salamanna F, Parrilli A, Martini L, Cadossi M, Maglio M, et al. Elec trochemotherapy is effective in the treatment of rat bone metastases. Clin Exp Metastasis 2013; 30: 1033-45. http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER-APP&SrcAuth=LinksAMR&KeyUT=WOS:000327854800008&DestLinkType=FullRecord&DestApp=ALL-WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3 10.1007/s10585-013-9601-x
10. Fini M, Tschon M, Ronchetti M, Cavani F, Bianchi G, Mercuri M, et al. Ablat ion of bone cells by electroporation. J Bone Joint Surg BR 2010; 92: 1614-20. 10.1302/0301-620X.92B11.24664
11. Edhemovic I, Brecelj E, Gasljevic G, Marolt Music M, Gorjup V, Mali B, et a l. Intraoperative electrochemotherapy of colorectal liver metastases. J Surg Oncol 2014; 110: 320-7. 10.1002/jso.23625
12. Sersa G, Stabuc B, Cemazar M, Jancar B, Miklavcic D, Rudolf Z. Electrochemo therapy with cisplatin: potentiation of local cisplatin antitumour effectiveness by application of electric pulses in cancer patients. Eur J Cancer 1998; 34: 1213-8. 10.1016/S0959-8049(98)00025-2
13. Sersa G, Stabuc B, Cemazar M, Miklavcic D, Rudolf Z. Electrochemotherapy wi th cisplatin: The systemic antitumour effectiveness of cisplatin can be potentiated locally by the application of electric pulses in the treatment of malignant melanoma skin metastases. Melanoma Res 2000; 10: 381-85. 10.1097/00008390-200008000-00010
14. Cemazar M, Miklavcic D, Vodovnik L, Jarm T, Rudolf Z, Stabuc B, et al. Impr oved therapeutic effect of electrochemotherapy with cisplatin by intratumoral drug administration and changing of electrode orientation for electropermeabilization on EAT tumors in mice. Radiol Oncol 1995; 29: 121-27.
15. Jarm T, Cemazar M, Miklavcic D, Sersa G. Antivascular effects of electroche motherapy: implications in treatment of bleeding metastases. Expert Rev Anticancer Ther 2010; 10: 729-46. 10.1586/era.10.43 http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER-APP&SrcAuth=LinksAMR&KeyUT=WOS:000278637500020&DestLinkType=FullRecord&DestApp=ALL-WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3
16. Calvet CY, Famin D, Andre FM, Mir LM. Electrochemotherapy with bleomycin in duces hallmarks of immunogenic cell death in murine colon cancer cells. Oncoimmunology 2014; 3: e28131. http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER-APP&SrcAuth=LinksAMR&KeyUT=WOS:000339955700001&DestLinkType=FullRecord&DestApp=ALL-WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3 10.4161/onci.28131
17. Goetz FW, Planas JV, MacKenzie S. Tumor necrosis factors. Dev Comp Immunol 2004; 28: 487-97. 10.1016/j.dci.2003.09.008 15062645
18. Mocellin S, Rossi CR, Pilati P, Nitti D. Tumor necrosis factor, cancer and anticancer therapy. Cytokine Growth F R 2005; 16: 35-53. 10.1016/j.cytogfr.2004.11.001
19. Cemazar M, Miklavcic D, Scancar J, Dolzan V, Golouh R, Sersa G. Increased p latinum accumulation in SA-1 tumour cells after in vivo electrochemotherapy with cisplatin. Brit J Cancer 1999; 79: 1386-91.
20. Campana LG, Mali B, Sersa G, Valpione S, Giorgi CA, Strojan P, et al. Elect rochemotherapy in non-melanoma head and neck cancers: a retrospective analysis of the treated cases. Br J Oral Maxillofac Surg 2014; 52: 957-64. 10.1016/j.bjoms.2014.08.004
21. Campana LG, Valpione S, Falci C, Mocellin S, Basso M, Corti L, et al. The a ctivity and safety of electrochemotherapy in persistent chest wall recurrence from breast cancer after mastectomy: a phase-II study. Breast Cancer Res Tr 2012; 134: 1169-78. 10.1007/s10549-012-2095-4 http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER-APP&SrcAuth=LinksAMR&KeyUT=WOS:000307273300025&DestLinkType=FullRecord&DestApp=ALL-WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3
22. Campana LG, Mocellin S, Basso M, Puccetti O, De Salvo GL, Chiarion-Sileni V, et al. Bleomycin-based electrochemotherapy: Clinical outcome from a single institution's experience with 52 patients. Ann Surg Oncol 2009; 16: 191-99. 10.1245/s10434-008-0204-8
23. Campana LG, Valpione S, Mocellin S, Sundararajan R, Granziera E, Sartore L, et al. Electrochemotherapy for disseminated superficial metastases from malignant melanoma. Brit J Surg 2012; 99: 821-30. http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER-APP&SrcAuth=LinksAMR&KeyUT=WOS:000303311600014&DestLinkType=FullRecord&DestApp=ALL-WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3 10.1002/bjs.8749
24. Mali B, Miklavcic D, Campana LG, Cemazar M, Sersa G, Snoj M, et al. Tumor s ize and effectiveness of electrochemotherapy. Radiol Oncol 2013; 47: 32-41. http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER-APP&SrcAuth=LinksAMR&KeyUT=WOS:000317464100005&DestLinkType=FullRecord&DestApp=ALL-WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3
25. Quaglino P, Mortera C, Osella-Abate S, Barberis M, Illengo M, Rissone M, et al. Electrochemotherapy with intravenous bleomycin in the local treatment of skin melanoma metastases. Ann Surg Oncol 2008; 15: 2215-22. http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER-APP&SrcAuth=LinksAMR&KeyUT=WOS:000257911300019&DestLinkType=FullRecord&DestApp=ALL-WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3 18498012 10.1245/s10434-008-9976-0
26. Sedlar A, Dolinsek T, Markelc B, Prosen L, Kranjc S, Bosnjak M, et al. Pote ntiation of electrochemotherapy by intramuscular IL-12 gene electrotransfer in murine sarcoma and carcinoma with different immunogenicity. Radiol Oncol 2012; 46: 302-11. http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER-APP&SrcAuth=LinksAMR&KeyUT=WOS:000311648100005&DestLinkType=FullRecord&DestApp=ALL-WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3
27. Heller L, Pottinger C, Jaroszeski MJ, Gilbert R, Heller R. In vivo electrop oration of plasmids encoding GM-CSF or interleukin-2 into existing B16 melanomas combined with electrochemotherapy induces long-term antitumour immunity. Melanoma Res 2000; 10: 577-83. 10.1097/00008390-200012000-00010
28. Torrero MN, Henk WG, Li S. Regression of high-grade malignancy in mice by b leomycin and interleukin-12 electrochemogenetherapy. Clin Cancer Res 2006; 12: 257-63.
29. Ramirez LH, Orlowski S, An D, Bindoula G, Dzodic R, Ardouin P, et al. Elect rochemotherapy on liver tumours in rabbits. Brit J Cancer 1998; 77: 2104-11. 10.1038/bjc.1998.354
30. Sersa G, Cemazar M, Menart V, Gaberc-Porekar V, Miklavcic D. Anti-tumor eff ectiveness of electrochemotherapy with bleomycin is increased by TNFalpha on SA-1 tumors in mice. Cancer Lett 1997; 116: 85-92.
31. Roberts NJ, Zhou S, Diaz LA, Jr., Holdhoff M. Systemic use of tumor necrosi s factor alpha as an anticancer agent. Oncotarget 2011; 2: 739-51.
32. Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer 2009; 9: 361-71. 19343034 http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER-APP&SrcAuth=LinksAMR&KeyUT=WOS:000265938800013&DestLinkType=FullRecord&DestApp=ALL-WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3 10.1038/nrc2628
33. Eisenthal A, Schwartz I, Issakov J, Klausner Y, Misonzhnik F, Lifschitz-Mer cer B. Immunohistochemistry evaluation of the effect in vivo of tumor necrosis factor (TNF)-alpha on blood vessel density in murine fibrosarcoma. Sarcoma 2003; 7: 57-61. 10.1080/13577140310001607275
34. Nooijen PT, Manusama ER, Eggermont AM, Schalkwijk L, Stavast J, Marquet RL, et al. Synergistic effects of TNF-alpha and melphalan in an isolated limb perfusion model of rat sarcoma: a histopathological, immunohistochemical and electron microscopical study. Brit J Cancer 1996; 74: 1908-15. 10.1038/bjc.1996.652
35. Kristensen CA, Nozue M, Boucher Y, Jain RK. Reduction of interstitial fluid pressure after TNF-alpha treatment of three human melanoma xenografts. Brit J Cancer 1996; 74: 533-6. 10.1038/bjc.1996.397
36. Lejeune FJ, Lienard D, Matter M, Ruegg C. Efficiency of recombinant human T NF in human cancer therapy. Cancer Immunity 2006; 6: 6.
37. Menon C, Ghartey A, Canter R, Feldman M, Fraker DL. Tumor necrosis factor- a lpha damages tumor blood vessel integrity by targeting VE-cadherin. Ann Surg 2006; 244: 781-91. 10.1097/01.sla.0000231723.81218.72
38. van Horssen R, Ten Hagen TL, Eggermont AM. TNF-alpha in cancer treatment: m olecular insights, antitumor effects, and clinical utility. Oncologist 2006; 11: 397-408. 10.1634/theoncologist.11-4-397
39. Folli S, Pelegrin A, Chalandon Y, Yao X, Buchegger F, Lienard D, et al. Tum ornecrosis factor can enhance radio-antibody uptake in human colon carcinoma xenografts by increasing vascular permeability. Int J Cancer 1993; 53: 829-36. 10.1002/ijc.2910530521
40. de Wilt JHW, ten Hagen TLM, de Boeck G, van Tiel ST, de Bruijn EA, Eggermon t AMM. Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion. Brit J Cancer 2000; 82: 1000-3. 10.1054/bjoc.1999.1032
41. Sersa G, Willingham V, Milas L. Anti-Tumor Effects of Tumor Necrosis Factor Alone or Combined with Radiotherapy. Int J Cancer 1988; 42: 129-34. 3391701 10.1002/ijc.2910420124